MADRIGAL PHARMACEUTICALS INC's ticker is MDGL and the CUSIP is 558868105. A total of 199 filers reported holding MADRIGAL PHARMACEUTICALS INC in Q4 2022. The put-call ratio across all filers is 1.76 and the average weighting 0.6%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $18,201,987 | -74.0% | 124,637 | -58.9% | 0.61% | -70.0% |
| Q2 2023 | $69,989,997 | -55.6% | 302,987 | -53.4% | 2.03% | -56.5% |
| Q1 2023 | $157,605,150 | -47.4% | 650,562 | -37.0% | 4.65% | -44.7% |
| Q4 2022 | $299,518,263 | +1292.3% | 1,031,932 | +211.7% | 8.41% | +1247.9% |
| Q3 2022 | $21,513,000 | -18.2% | 331,023 | -9.9% | 0.62% | -24.3% |
| Q2 2022 | $26,306,000 | -3.7% | 367,501 | +32.1% | 0.82% | +50.6% |
| Q1 2022 | $27,305,000 | +86.5% | 278,286 | +61.0% | 0.55% | +384.1% |
| Q4 2021 | $14,644,000 | +2989.5% | 172,800 | +7708.4% | 0.11% | +769.2% |
| Q3 2018 | $474,000 | -94.7% | 2,213 | -93.1% | 0.01% | -94.5% |
| Q2 2018 | $9,010,000 | -45.9% | 32,213 | -77.4% | 0.24% | -49.4% |
| Q1 2018 | $16,645,000 | -4.0% | 142,522 | -24.5% | 0.47% | -19.0% |
| Q4 2017 | $17,338,000 | – | 188,893 | – | 0.58% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Avoro Capital Advisors LLC | 1,425,000 | $113,701,000 | 1.79% |
| L1 Capital Pty Ltd | 164,860 | $13,154,000 | 1.64% |
| ARMISTICE CAPITAL, LLC | 1,036,000 | $82,662,000 | 1.40% |
| Tao Capital Management LP | 51,396 | $4,101,000 | 1.09% |
| Parkman Healthcare Partners LLC | 31,393 | $2,505,000 | 0.63% |
| Baker Brothers Advisors | 1,499,213 | $119,622,000 | 0.52% |
| Rock Springs Capital Management LP | 262,500 | $20,945,000 | 0.44% |
| ORACLE INVESTMENT MANAGEMENT INC | 38,500 | $3,072,000 | 0.38% |
| Capital Impact Advisors, LLC | 11,775 | $940,000 | 0.37% |
| Hennion & Walsh Asset Management, Inc. | 73,936 | $5,899,000 | 0.31% |